Aim: To compare immuno enriched formula with a standard feeding regiment regarding perioperative
immune response and clinical outcome.
Patients and Material: 46 (31 male; 15 female) with upper gastro-intestinal cancer (pancreas, stomach) were
randomized into three groups. Group I (14) received for 5 days preoperative and seven
days postoperative Impact®. Group II (17) two days preoperative and seven days postoperative
Impact plus ®. Control Group III (15) received only postoperative Impact® for seven
days. The rate of postoperative infections, ICU stay and hospital stay were recorded.
Results: The lowest infection rate was observed in group I and II. (14%; 29%). The highest
in group III (67%). No significant difference was observed between the three groups
regarding non-infectious complications (43%; 47% and 67%). ICU and hospital stay were
significant increased for group III compared to group I and II. Perioperative endotoxin
levels were significant lower in group I and II (max. 0.1 EU/ml) compared to group
III (max 0.3 EU/ml).
Conclusions: Preoperative immunonutrition offers a significant better perioperative outcome regarding
perioperative immune response and endotoxemia. Clinical outcome may also be positively
affected with preoperative immunonutrition.